Trial Profile
Sitagliptin for the Prevention and Treatment of Stress Hyperglycemia in Non-Diabetic Patients Undergoing Cardiac Surgery
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Insulin; Insulin aspart; Insulin glargine; Insulin lispro
- Indications Coronary artery disease; Hyperglycaemia
- Focus Therapeutic Use
- Acronyms SITA-CABG; SITACABG NonDM
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 31 Jan 2017 Status changed from recruiting to completed.
- 26 Jan 2016 Planned number of patients changed from 50 to 60, as reported by ClinicalTrials.gov.